351 related articles for article (PubMed ID: 17522861)
21. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.
Bayry J; Tchilian EZ; Davies MN; Forbes EK; Draper SJ; Kaveri SV; Hill AV; Kazatchkine MD; Beverley PC; Flower DR; Tough DF
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10221-6. PubMed ID: 18621704
[TBL] [Abstract][Full Text] [Related]
22. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Heimberger AB; Abou-Ghazal M; Reina-Ortiz C; Yang DS; Sun W; Qiao W; Hiraoka N; Fuller GN
Clin Cancer Res; 2008 Aug; 14(16):5166-72. PubMed ID: 18698034
[TBL] [Abstract][Full Text] [Related]
23. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Lee DJ; Sharma N; Dubeau L; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2014 Aug; 13(8):2004-17. PubMed ID: 24994771
[TBL] [Abstract][Full Text] [Related]
24. A high-throughput chemotaxis detection method for CCR4
Magnotti EL; Chan LL; Zhu Q; Marasco WA
J Immunol Methods; 2020 Apr; 479():112747. PubMed ID: 31958449
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma.
Shono K; Yamaguchi I; Mizobuchi Y; Kagusa H; Sumi A; Fujihara T; Nakajima K; Kitazato KT; Matsuzaki K; Saya H; Takagi Y
Sci Rep; 2020 Sep; 10(1):15286. PubMed ID: 32943658
[TBL] [Abstract][Full Text] [Related]
26. Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation.
Maru SV; Holloway KA; Flynn G; Lancashire CL; Loughlin AJ; Male DK; Romero IA
J Neuroimmunol; 2008 Aug; 199(1-2):35-45. PubMed ID: 18538864
[TBL] [Abstract][Full Text] [Related]
27. CCL22 Signaling in the Tumor Environment.
Röhrle N; Knott MML; Anz D
Adv Exp Med Biol; 2020; 1231():79-96. PubMed ID: 32060848
[TBL] [Abstract][Full Text] [Related]
28. CCL22-producing CD8α- myeloid dendritic cells mediate regulatory T cell recruitment in response to G-CSF treatment.
Layseca-Espinosa E; Korniotis S; Montandon R; Gras C; Bouillié M; Gonzalez-Amaro R; Dy M; Zavala F
J Immunol; 2013 Sep; 191(5):2266-72. PubMed ID: 23878314
[TBL] [Abstract][Full Text] [Related]
29. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.
Viney JM; Andrew DP; Phillips RM; Meiser A; Patel P; Lennartz-Walker M; Cousins DJ; Barton NP; Hall DA; Pease JE
J Immunol; 2014 Apr; 192(7):3419-27. PubMed ID: 24563252
[TBL] [Abstract][Full Text] [Related]
30. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis.
Zhang J; Sarkar S; Cua R; Zhou Y; Hader W; Yong VW
Carcinogenesis; 2012 Feb; 33(2):312-9. PubMed ID: 22159219
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
32. C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation.
Chiang Y; Lu LF; Tsai CL; Tsai YC; Wang CC; Hsueh FJ; Huang CY; Chen CH; Pu YS; Cheng JC
Eur J Cancer; 2024 Feb; 198():113521. PubMed ID: 38171115
[TBL] [Abstract][Full Text] [Related]
33. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
[TBL] [Abstract][Full Text] [Related]
34. IL-4/CCL22/CCR4 axis controls regulatory T-cell migration that suppresses inflammatory bone loss in murine experimental periodontitis.
Araujo-Pires AC; Vieira AE; Francisconi CF; Biguetti CC; Glowacki A; Yoshizawa S; Campanelli AP; Trombone AP; Sfeir CS; Little SR; Garlet GP
J Bone Miner Res; 2015 Mar; 30(3):412-22. PubMed ID: 25264308
[TBL] [Abstract][Full Text] [Related]
35. Distinctive Treg associated CCR4-CCL22 expression profile with altered frequency of Th17/Treg cell in the immunopathogenesis of Pemphigus Vulgaris.
Asothai R; Anand V; Das D; Antil PS; Khandpur S; Sharma VK; Sharma A
Immunobiology; 2015 Oct; 220(10):1129-35. PubMed ID: 26093920
[TBL] [Abstract][Full Text] [Related]
36. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
37. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus.
Lee HY; Hong YK; Yun HJ; Kim YM; Kim JR; Yoo WH
Rheumatology (Oxford); 2008 Jun; 47(6):789-94. PubMed ID: 18388146
[TBL] [Abstract][Full Text] [Related]
38. FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Patil AA; Sayal P; Depondt ML; Beveridge RD; Roylance A; Kriplani DH; Myers KN; Cox A; Jellinek D; Fernando M; Carroll TA; Collis SJ
Oncotarget; 2014 Aug; 5(15):6414-24. PubMed ID: 25071006
[TBL] [Abstract][Full Text] [Related]
39. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
Ishida T; Ishii T; Inagaki A; Yano H; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Res; 2006 Jun; 66(11):5716-22. PubMed ID: 16740709
[TBL] [Abstract][Full Text] [Related]
40. The role of regulatory T cells in malignant glioma.
Sonabend AM; Rolle CE; Lesniak MS
Anticancer Res; 2008; 28(2B):1143-50. PubMed ID: 18505050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
